The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies

McKay, Fiona C., Gatt, Prudence N., Fewings, Nicole, Parnell, Grant P., Schibeci, Stephen D., Basuki, Monica A. I., Powell, Joseph E., Goldinger, Anita, Fabis-Pedrini, Marzena J., Kermode, Allan G., Burke, Therese, Vucic, Steve, Stewart, Graeme J. and Booth, David R. (2016) The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clinical Immunology, 163 96-107. doi:10.1016/j.clim.2015.12.015

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author McKay, Fiona C.
Gatt, Prudence N.
Fewings, Nicole
Parnell, Grant P.
Schibeci, Stephen D.
Basuki, Monica A. I.
Powell, Joseph E.
Goldinger, Anita
Fabis-Pedrini, Marzena J.
Kermode, Allan G.
Burke, Therese
Vucic, Steve
Stewart, Graeme J.
Booth, David R.
Title The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies
Journal name Clinical Immunology   Check publisher's open access policy
ISSN 1521-7035
1521-6616
Publication date 2016-02-01
Year available 2016
Sub-type Article (original research)
DOI 10.1016/j.clim.2015.12.015
Open Access Status File (Author Post-print)
Volume 163
Start page 96
End page 107
Total pages 12
Place of publication Maryland Heights, MO, United States
Publisher Academic Press
Collection year 2017
Language eng
Formatted abstract
Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p<0.0007 for EOMES, p<0.028 for TBX21) and demonstrate longitudinal stability (p<10-4) and high heritability (h2=0.48 for EOMES) for this molecular phenotype. Genes whose expression correlated with ET, especially those controlling cell migration, further defined the phenotype. CD56+ cells and other subsets expressed lower levels of Eomes or T-bet protein and/or were under-represented in MS. EOMES and TBX21 risk SNP genotypes, and serum EBNA-1 titres were not correlated with ET expression, but HLA-DRB1*1501 genotype was. ET expression was normalised to healthy control levels with natalizumab, and was highly variable for glatiramer acetate, fingolimod, interferon-beta, dimethyl fumarate.
Keyword Biomarker
EOMES
Gene expression
MS risk gene
Multiple sclerosis
Natalizumab
TBX21
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 02 Feb 2016, 00:23:57 EST by System User on behalf of Learning and Research Services (UQ Library)